<DOC>
	<DOCNO>NCT02320435</DOCNO>
	<brief_summary>This single-arm , multi-center , open-label extension study design provide pertuzumab patient continue derive benefit pertuzumab , well collect long-term safety efficacy data pertuzumab therapy . Patients receive pertuzumab investigational medicinal product ( IMP ) Roche-sponsored Global study continue receive pertuzumab time Parent study end eligible continued treatment extension study . Patients solid tumor experience progressive disease Parent study , Investigator 's opinion , may potentially benefit continued Perjeta treatment continue receive pertuzumab disease progression , unacceptable toxicity , Investigator decision , patient non-compliance , patient death , patient request withdraw , study termination Sponsor .</brief_summary>
	<brief_title>A Safety Efficacy Extension Study Pertuzumab Patients With Solid Tumors Previously Enrolled Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Informed consent Prior eligibility , receive pertuzumab investigational medicinal product , Rochesponsored study ( either single agent combination anticancer drug use Parent study ) time Parent study closure Investigator 's opinion patient continue benefit treatment Meets exclusion criterion Parent protocol time patient consider entry extension study Evidence disease progression assess accord Parent protocol enrollment extension study Permanent discontinuation pertuzumab reason Parent study , end Parent study enrollment extension study Any unresolved irreversible toxicity Parent study require permanent discontinuation pertuzumab , accord Parent protocol local label . Delay treatment wait resolution toxicity allow long within guideline respective Parent protocol contradict exclusion criterion . More 9 week last dose pertuzumab Parent study first dose pertuzumab extension study Left ventricular ejection fraction &lt; /= 50 % Any serious uncontrolled concomitant disease would contraindicate use pertuzumab would put patient high risk treatmentrelated complication Treatment anticancer treatment ( treatment give permit Parent protocol ) time period last treatment Parent study first dose pertuzumab extension study ( i.e . 9 week ) Positive serum pregnancy test Women childbearing potential sexually active agree use highly effective , nonhormonal form contraception two effective form nonhormonal contraception ( barrier method conjunction spermicidal gel ) least 6 month last dose pertuzumab 7 month last dose trastuzumab trastuzumab emtansine ( TDM1 ) , use combination Concurrent participation therapeutic clinical trial ( Parent study ) Assessed Investigator unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>